Many studies suggest that combining novel immune checkpoint inhibitors with traditional ICIs (such as PD-1/PD-L1 and CTLA-4 inhibitors) could significantly improve cancer treatment outcomes and patient survival. This evidence concerns the gene CTLA4 and cancer.